Sino Biopharmaceutical’s Culmerciclib Capsule Gains Approval for Breast Cancer Treatment

Sino Biopharmaceutical ( (HK:1177) ) just unveiled an update.

Sino Biopharmaceutical Limited announced that its self-developed drug, culmerciclib capsule, has been approved by the China National Medical Products Administration for marketing. This innovative drug, used in combination with fulvestrant, targets HR-positive, HER2-negative advanced breast cancer, showing significant efficacy in clinical trials by prolonging progression-free survival and improving response rates with a tolerable safety profile. The approval marks a significant milestone in addressing the unmet clinical needs in breast cancer treatment and strengthens the company’s position in the oncology market. The company is also pursuing further approvals for culmerciclib in first-line treatment and adjuvant use, highlighting its commitment to expanding treatment options for breast cancer patients.

The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in the development of innovative drugs, particularly in the field of oncology, with a market focus on breast cancer treatments. The company has developed a comprehensive pipeline that covers various subtypes of breast cancer, including HR-positive, HER2-positive, HER2-low, and triple-negative breast cancer, spanning the entire treatment cycle from adjuvant to subsequent lines of treatment.

Average Trading Volume: 89,295,158

Technical Sentiment Signal: Buy

Current Market Cap: HK$121.1B

For an in-depth examination of 1177 stock, go to TipRanks’ Overview page.